Literature DB >> 20060365

DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia.

Maria E Figueroa1, Sanne Lugthart, Yushan Li, Claudia Erpelinck-Verschueren, Xutao Deng, Paul J Christos, Elizabeth Schifano, James Booth, Wim van Putten, Lucy Skrabanek, Fabien Campagne, Madhu Mazumdar, John M Greally, Peter J M Valk, Bob Löwenberg, Ruud Delwel, Ari Melnick.   

Abstract

We hypothesized that DNA methylation distributes into specific patterns in cancer cells, which reflect critical biological differences. We therefore examined the methylation profiles of 344 patients with acute myeloid leukemia (AML). Clustering of these patients by methylation data segregated patients into 16 groups. Five of these groups defined new AML subtypes that shared no other known feature. In addition, DNA methylation profiles segregated patients with CEBPA aberrations from other subtypes of leukemia, defined four epigenetically distinct forms of AML with NPM1 mutations, and showed that established AML1-ETO, CBFb-MYH11, and PML-RARA leukemia entities are associated with specific methylation profiles. We report a 15 gene methylation classifier predictive of overall survival in an independent patient cohort (p < 0.001, adjusted for known covariates). Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20060365      PMCID: PMC3008568          DOI: 10.1016/j.ccr.2009.11.020

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  29 in total

1.  Gene Expression Omnibus: NCBI gene expression and hybridization array data repository.

Authors:  Ron Edgar; Michael Domrachev; Alex E Lash
Journal:  Nucleic Acids Res       Date:  2002-01-01       Impact factor: 16.971

2.  World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

Authors:  N L Harris; E S Jaffe; J Diebold; G Flandrin; H K Muller-Hermelink; J Vardiman; T A Lister; C D Bloomfield
Journal:  J Clin Oncol       Date:  1999-12       Impact factor: 44.544

3.  Methylation profiling in acute myeloid leukemia.

Authors:  M Toyota; K J Kopecky; M O Toyota; K W Jair; C L Willman; J P Issa
Journal:  Blood       Date:  2001-05-01       Impact factor: 22.113

4.  DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development.

Authors:  M Okano; D W Bell; D A Haber; E Li
Journal:  Cell       Date:  1999-10-29       Impact factor: 41.582

5.  Functional association of CTCF with the insulator upstream of the H19 gene is parent of origin-specific and methylation-sensitive.

Authors:  C Kanduri; V Pant; D Loukinov; E Pugacheva; C F Qi; A Wolffe; R Ohlsson; V V Lobanenkov
Journal:  Curr Biol       Date:  2000-07-13       Impact factor: 10.834

6.  Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome.

Authors:  Bas J Wouters; Bob Löwenberg; Claudia A J Erpelinck-Verschueren; Wim L J van Putten; Peter J M Valk; Ruud Delwel
Journal:  Blood       Date:  2009-01-26       Impact factor: 22.113

7.  Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia.

Authors:  D H Christiansen; M K Andersen; J Pedersen-Bjergaard
Journal:  Leukemia       Date:  2003-09       Impact factor: 11.528

8.  Prognostically useful gene-expression profiles in acute myeloid leukemia.

Authors:  Peter J M Valk; Roel G W Verhaak; M Antoinette Beijen; Claudia A J Erpelinck; Sahar Barjesteh van Waalwijk van Doorn-Khosrovani; Judith M Boer; H Berna Beverloo; Michael J Moorhouse; Peter J van der Spek; Bob Löwenberg; Ruud Delwel
Journal:  N Engl J Med       Date:  2004-04-15       Impact factor: 91.245

9.  Bioconductor: open software development for computational biology and bioinformatics.

Authors:  Robert C Gentleman; Vincent J Carey; Douglas M Bates; Ben Bolstad; Marcel Dettling; Sandrine Dudoit; Byron Ellis; Laurent Gautier; Yongchao Ge; Jeff Gentry; Kurt Hornik; Torsten Hothorn; Wolfgang Huber; Stefano Iacus; Rafael Irizarry; Friedrich Leisch; Cheng Li; Martin Maechler; Anthony J Rossini; Gunther Sawitzki; Colin Smith; Gordon Smyth; Luke Tierney; Jean Y H Yang; Jianhua Zhang
Journal:  Genome Biol       Date:  2004-09-15       Impact factor: 13.583

10.  Semi-supervised methods to predict patient survival from gene expression data.

Authors:  Eric Bair; Robert Tibshirani
Journal:  PLoS Biol       Date:  2004-04-13       Impact factor: 8.029

View more
  345 in total

1.  Mutant WT1 is associated with DNA hypermethylation of PRC2 targets in AML and responds to EZH2 inhibition.

Authors:  Subarna Sinha; Daniel Thomas; Linda Yu; Andrew J Gentles; Namyoung Jung; M Ryan Corces-Zimmerman; Steven M Chan; Andreas Reinisch; Andrew P Feinberg; David L Dill; Ravindra Majeti
Journal:  Blood       Date:  2014-11-14       Impact factor: 22.113

2.  DNA methylation screening identifies driver epigenetic events of cancer cell survival.

Authors:  Daniel D De Carvalho; Shikhar Sharma; Jueng Soo You; Sheng-Fang Su; Phillippa C Taberlay; Theresa K Kelly; Xiaojing Yang; Gangning Liang; Peter A Jones
Journal:  Cancer Cell       Date:  2012-05-15       Impact factor: 31.743

3.  DNMT3B7, a truncated DNMT3B isoform expressed in human tumors, disrupts embryonic development and accelerates lymphomagenesis.

Authors:  Mrinal Y Shah; Aparna Vasanthakumar; Natalie Y Barnes; Maria E Figueroa; Anna Kamp; Christopher Hendrick; Kelly R Ostler; Elizabeth M Davis; Shang Lin; John Anastasi; Michelle M Le Beau; Ivan P Moskowitz; Ari Melnick; Peter Pytel; Lucy A Godley
Journal:  Cancer Res       Date:  2010-06-29       Impact factor: 12.701

4.  Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/MDS.

Authors:  Xin Zhao; Xin Tian; Sachiko Kajigaya; Caroline R Cantilena; Stephen Strickland; Bipin N Savani; Sanjay Mohan; Xingmin Feng; Keyvan Keyvanfar; Neil Dunavin; Danielle M Townsley; Bogdan Dumitriu; Minoo Battiwalla; Katayoun Rezvani; Neal S Young; A John Barrett; Sawa Ito
Journal:  Br J Haematol       Date:  2016-07-19       Impact factor: 6.998

5.  AML1/ETO cooperates with HIF1α to promote leukemogenesis through DNMT3a transactivation.

Authors:  X N Gao; F Yan; J Lin; L Gao; X L Lu; S C Wei; N Shen; J X Pang; Q Y Ning; Y Komeno; A L Deng; Y H Xu; J L Shi; Y H Li; D E Zhang; C Nervi; S J Liu; L Yu
Journal:  Leukemia       Date:  2015-03-02       Impact factor: 11.528

6.  "Epigenetic" modification as therapy for acute myeloid leukemia.

Authors:  Charles A Schiffer
Journal:  Cancer       Date:  2017-12-06       Impact factor: 6.860

Review 7.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

Review 8.  Concise review: Leukemia stem cells in personalized medicine.

Authors:  Monica L Guzman; John N Allan
Journal:  Stem Cells       Date:  2014-04       Impact factor: 6.277

9.  TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis.

Authors:  Pilar M Dominguez; Hussein Ghamlouch; Wojciech Rosikiewicz; Parveen Kumar; Wendy Béguelin; Lorena Fontán; Martín A Rivas; Patrycja Pawlikowska; Marine Armand; Enguerran Mouly; Miguel Torres-Martin; Ashley S Doane; María T Calvo Fernandez; Matt Durant; Veronique Della-Valle; Matt Teater; Luisa Cimmino; Nathalie Droin; Saber Tadros; Samaneh Motanagh; Alan H Shih; Mark A Rubin; Wayne Tam; Iannis Aifantis; Ross L Levine; Olivier Elemento; Giorgio Inghirami; Michael R Green; Maria E Figueroa; Olivier A Bernard; Said Aoufouchi; Sheng Li; Rita Shaknovich; Ari M Melnick
Journal:  Cancer Discov       Date:  2018-10-01       Impact factor: 39.397

10.  Genetic Characterization and Prognostic Relevance of Acquired Uniparental Disomies in Cytogenetically Normal Acute Myeloid Leukemia.

Authors:  Christopher J Walker; Jessica Kohlschmidt; Ann-Kathrin Eisfeld; Krzysztof Mrózek; Sandya Liyanarachchi; Chi Song; Deedra Nicolet; James S Blachly; Marius Bill; Dimitrios Papaioannou; Christopher C Oakes; Brian Giacopelli; Luke K Genutis; Sophia E Maharry; Shelley Orwick; Kellie J Archer; Bayard L Powell; Jonathan E Kolitz; Geoffrey L Uy; Eunice S Wang; Andrew J Carroll; Richard M Stone; John C Byrd; Albert de la Chapelle; Clara D Bloomfield
Journal:  Clin Cancer Res       Date:  2019-08-02       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.